Skip to main content
TRAW
NASDAQ Life Sciences

Traws Pharma Q2 2026: Going Concern, Nasdaq Delisting Risk, and $50M Warrant Overhang

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.571
Mkt Cap
$8.695M
52W Low
$0.43
52W High
$3.265
52W Position info
33% above low
Off High info
83% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

TRAW sits 33% above its 52-week low of $0.43 on light trading volume (0.2× avg).

Summary

Traws Pharma's Q2 2026 filing reveals a going concern warning, Nasdaq delisting risk, and a massive warrant overhang from its April financing, all while its lead drug program faces regulatory setbacks.


Key Events · Earnings and Guidance · TRAW

  • Going Concern Warning Reiterated

    Cash of $5.0 million and accumulated deficit of $650.1 million as of June 30, 2026. Management states substantial doubt about ability to continue as a going concern within one year.

  • Nasdaq Delisting Notice

    Received July 29, 2026, for stock price below $1.00 for 30 consecutive days. Compliance deadline is January 25, 2027. Company may need a reverse stock split.

  • FDA Clinical Hold on Lead Program

    U.S. IND for tivoxavir marboxil placed on clinical hold due to toxicology data concerns. Company aims to resolve by end of 2026.

  • Massive Warrant Overhang

    April 2026 financing issued warrants for up to 29,914,595 shares at $1.673 exercise price, potentially raising $50 million but causing extreme dilution if exercised.


Analysis · TRAW · Life Sciences

Traws Pharma's Q2 2026 report confirms the company has only $5.0 million in cash against an accumulated deficit of $650.1 million, with management stating substantial doubt about its ability to continue as a going concern. The company also faces a Nasdaq delisting notice received July 29, 2026, with a compliance deadline of January 25, 2027, and an FDA clinical hold on its lead influenza candidate. The April 2026 financing brought in $10 million upfront but created warrants for up to 29.9 million additional shares that could raise $50 million if exercised, representing massive potential dilution. These factors combine to create a critical situation for existing shareholders.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TRAW was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.43 to $3.27. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TRAW - Latest Insights

TRAW
Nov 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.252
Real-time Price: $0.244929 info
Change: -$0.007071 (-3%) info
Market Cap: $3.857M info
TRAW
Oct 26, 2026, 4:47 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.350
Real-time Price: $0.244929 info
Change: -$0.105071 (-30%) info
Market Cap: $3.857M info
TRAW
Oct 23, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3425
Real-time Price: $0.244929 info
Change: -$0.097571 (-28%) info
Market Cap: $3.857M info
TRAW
Oct 20, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3767
Real-time Price: $0.244929 info
Change: -$0.131771 (-35%) info
Market Cap: $3.857M info
TRAW
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4803
Real-time Price: $0.244929 info
Change: -$0.235371 (-49%) info
Market Cap: $3.857M info